Development of DDR-based cancer therapies, focusing on ATR and Polθ inhibitors.
E
CSR Analysis score
The organization does not position itself on any CSR axis.
EmpCo Directive — September 27, 2026
We analyzed the websites of over 250,000 companies, including Artios Pharma's, to extract CSR initiatives and communications containing risky environmental claims.
Greenwashing risk score + your position within your sector
+250,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: May 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
Oncodesign
B
Development of innovative therapeutic and diagnostic solutions to treat therapeutic resistance and metastasis evolution, with a focus on precision medicine.
Myricx Pharma
C
Development of cancer treatments based on NMT inhibition for antibody-drug conjugates.
Redona Therapeutics
E
Development of novel therapeutics targeting RNA and DNA-processing enzymes to treat serious diseases such as cancer and autoimmune diseases.
Initiatives identified among leaders
Mesure et réduction collaborative de l'empreinte carbone depuis 2022
“Depuis septembre 2022, Oncodesign mesure son empre...” - OncodesignDialogue social et engagement collaborateur pour projets locaux et éthique professionnelle
“OPM s’engage à adopter un dialogue social pour ren...” - Oncodesign33% of similar organizations communicate on CSR issues
+19 initiatives collected from 49 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports